"Alan Mendelson has a national reputation for his work with early stage and established companies in the life sciences industry. He brings an enviable level of experience to the table for his clients and is 'highly responsive, and the quality of his work is top-notch.'"

Chambers USA 2016

Alan C. Mendelson

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA

Alan Mendelson, widely recognized as one of the most respected and experienced lawyers in the life sciences industry, helps companies grow through every stage of the business life cycle. He draws on insights gained from decades of experience counseling the boards and executives of emerging and public companies, both as an advisor on transactions and as outside general counsel.

Mr. Mendelson advises startups, market-leading companies, and the investment banks that finance them on a full range of transactions, including:

  • Venture capital financings
  • Private placements
  • Public offerings
  • Mergers and acquisitions
  • Joint ventures
  • Strategic collaborations
  • Commercial transactions

He also serves as the corporate secretary for many public and private companies.

Mr. Mendelson draws on significant experience with Amgen, including as counsel from inception, serving as Secretary and Acting General Counsel, helping the company grow through multiple transactions, including: its major round of venture capital financing, IPO, a joint venture with Kirin Brewery, major research and development partnerships, a European convertible debt deal and a co-promotion agreement for Europe with Roche.

Industry and Community Leadership

Given his life sciences business acumen, Mr. Mendelson is an integral and active member of the life sciences academic, research, and business communities.

His current leadership roles include serving on the:

  • Board of Directors of the California Life Sciences Association (CLSA)
  • Board of Trustees of the UC Berkeley Foundation
  • Board of Advisors for the UC Berkeley Department of Chemistry
  • UC Innovation Council – advising UC President Janet Napolitano on technology and entrepreneurship initiatives for the UC system

Mr. Mendelson’s prior leadership roles include serving on the:

  • Board of Directors of the Biotechnology Industry Organization (BIO)
  • Board of Trustees of The Scripps Research Institute
  • BayBio Board of Directors
  • Cal Alumni Association, President
  • National Kidney Foundation of Northern California, President
  • Board of Regents of the University of California
  • Board of Overseers Visiting Committee of Harvard Law School
  • Major Gifts Council for the Lucile Packard Foundation for Children’s Health
  • Board of the American Friends of Rambam Medical Center, Haifa, Israel

Mr. Mendelson currently serves as principal outside or general counsel to numerous companies including:

  • 4D Molecular Therapeutics
  • Aduro Biotech
  • Antiva Biosciences
  • Blade Therapeutics
  • Chrono Therapeutics
  • Coherus BioSciences
  • Corcept Therapeutics
  • Corvus Pharmaceuticals
  • Frontier Medicines
  • Gritstone Oncology
  • Intuitive Surgical
  • Mellanox Technologies
  • OrphoMed
  • PellePharm
  • Prothena Biosciences
  • Satsuma Pharmaceuticals
  • Sienna Biopharmaceuticals
  • Singulex
  • Whole Biome
  • Zosano Pharma

As company counsel, he has handled public offerings for such notable companies as:

  • Amgen
  • Ardelyx
  • Axys Pharmaceuticals
  • Aviron
  • Coherus BioSciences
  • Complete Genomics
  • Corcept Therapeutics
  • Corvus Pharmaceuticals
  • CV Therapeutics
  • Geron Corporation
  • Gritstone Oncology
  • Intuitive Surgical
  • InterMune
  • Kythera Biopharmaceuticals
  • Mellanox Technologies
  • OncoMed Pharmaceuticals
  • Prothena Biosciences
  • Relypsa
  • Renovis
  • Sienna Biopharmaceuticals
  • Transcept Pharmaceuticals
  • Zosano Pharma

Avertissement : Nous vous remercions de l’intérêt que vous portez à Latham & Watkins. Si vous souhaitez nous confier un dossier mais que vous n'êtes pas encore client du cabinet, merci de ne nous transmettre aucune information confidentielle. Nous ne pouvons pas accepter un dossier avant de nous être assurés que nous sommes en mesure de vous assister et d’avoir trouvé un accord avec vous sur les termes et conditions de notre intervention. Dans la mesure où nous n’aurons pas de relation avocat-client avec vous auparavant, nous n’aurons aucune obligation de confidentialité à l’égard des informations que vous nous auriez transmises. Merci de votre compréhension.